UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 61

Sortiert nach

Considerations for pre‐transfusion immunohaematology testing in patients receiving the anti‐CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma

Internal medicine journal, 2018-02, Vol.48 (2), p.210-220

2018

Volltextzugriff (PDF)

Statin-induced anti-HMGCR antibody-related immune-mediated necrotising myositis achieving complete remission with rituximab

BMJ case reports, 2019-12, Vol.12 (11), p.e232406

2019

Volltextzugriff (PDF)

Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells

Frontiers in immunology, 2020-09, Vol.11, p.2153-2153

2020

Volltextzugriff (PDF)

Australia and New Zealand consensus position statement: use of COVID‐19 therapeutics in patients with haematological malignancies

Internal medicine journal, 2024-02, Vol.54 (2), p.328-336

2024

Volltextzugriff (PDF)

An Update on the Current Genomic Landscape of Breast Implant-Associated Anaplastic Large Cell Lymphoma

Cancers, 2021-09, Vol.13 (19), p.4921

2021

Volltextzugriff (PDF)

Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy

International journal of molecular sciences, 2018-06, Vol.19 (6), p.1758

2018

Volltextzugriff (PDF)

Epigenetic Modifications in Lymphoma and Their Role in the Classification of Lymphomas

Hemato, 2022-03, Vol.3 (1), p.174-187

2022

Volltextzugriff (PDF)

1528 A phase I study of a novel BCMA×CD3 bispecific antibody EMB06 in relapsed or refractory multiple myeloma

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 2), p.A1753-A1753

2023

Volltextzugriff (PDF)

Prognostic impact of monocyte count at presentation in mantle cell lymphoma

British journal of haematology, 2014-03, Vol.164 (6), p.890-893

2014

Volltextzugriff (PDF)

Dietary intake of animal-based products and likelihood of follicular lymphoma and survival: A population-based family case-control study

Frontiers in nutrition (Lausanne), 2023-01, Vol.9, p.1048301-1048301

2023

Volltextzugriff (PDF)

Inflammatory Pseudotumor of the Spleen

Hematology reports, 2015-06, Vol.7 (2), p.5905-5905

2015

Volltextzugriff (PDF)

Pralatrexate and angioimmunoblastic T-cell lymphoma: time for a second look?

Leukemia & lymphoma, 2020-07, Vol.61 (9), p.2031-2033

2020

Volltextzugriff (PDF)

A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL)

Blood, 2021-11, Vol.138 (Supplement 1), p.2436-2436

2021

Volltextzugriff (PDF)

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)

Blood, 2022-11, Vol.140 (Supplement 1), p.9399-9401

2022

Volltextzugriff (PDF)

Emerging drugs for T-cell lymphoma

Expert opinion on emerging drugs, 2014-06, Vol.19 (2), p.201-213

2014

Volltextzugriff (PDF)

Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study

Leukemia & lymphoma, 2021-01, Vol.62 (2), p.330-336

2021

Volltextzugriff (PDF)

A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma

Leukemia & lymphoma, 2019-03, Vol.60 (4), p.904-911

2019

Volltextzugriff (PDF)

Trends in the surgical management of stage 1 renal cell carcinoma: findings from a population‐based study

BJU international, 2017-11, Vol.120 (S3), p.6-14

2017

Volltextzugriff (PDF)

MM-040: Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m2 and Once-Weekly at 70 mg/m2 in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies

Clinical lymphoma, myeloma and leukemia, 2020-09, Vol.20, p.S288-S288

2020

Volltextzugriff (PDF)

Prognostic Value of Lymph Node Ratio in Patients with Uterine Carcinosarcoma

Journal of personalized medicine, 2024-01, Vol.14 (2), p.155

2024

Volltextzugriff (PDF)

Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasms

Epigenomics, 2016-01, Vol.8 (1), p.55-66

2016

Volltextzugriff (PDF)

The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit

American journal of hematology, 2015-05, Vol.90 (5), p.E86-E91

2015

Volltextzugriff (PDF)

Use of romidepsin for the treatment of mycosis fungoides and Sezary syndrome - role of romidepsin in the current therapeutic landscape and implications for future practice

Expert opinion on orphan drugs, 2015-10, Vol.3 (10), p.1231-1239

2015

Volltextzugriff (PDF)

1 – 25 von 61

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(57)
Berichte
(4)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(41)
Science & Technology
(41)
Humans
(31)
Aged
(27)
Male
(24)
Female
(23)
Middle Aged
(23)
Adult
(20)
Hematology
(19)
Oncology
(19)
Aged, 80 And Over
(15)
Lymphoma
(10)
Treatment Outcome
(10)
General & Internal Medicine
(9)
Medicine, General & Internal
(9)
Retrospective Studies
(9)
Vidarabine - Analogs & Derivatives
(9)
Biological And Medical Sciences
(8)
Hematologic And Hematopoietic Diseases
(8)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Considerations for pre‐transfusion immunohaematology testing in patients receiving the anti‐CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma

Statin-induced anti-HMGCR antibody-related immune-mediated necrotising myositis achieving complete remission with rituximab

Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic

Australia and New Zealand consensus position statement: use of COVID‐19 therapeutics in patients with haematological malignancies

An Update on the Current Genomic Landscape of Breast Implant-Associated Anaplastic Large Cell Lymphoma

Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy

Epigenetic Modifications in Lymphoma and Their Role in the Classification of Lymphomas

1528 A phase I study of a novel BCMA×CD3 bispecific antibody EMB06 in relapsed or refractory multiple myeloma

Prognostic impact of monocyte count at presentation in mantle cell lymphoma

Dietary intake of animal-based products and likelihood of follicular lymphoma and survival: A population-based family case-control study

Inflammatory Pseudotumor of the Spleen

Pralatrexate and angioimmunoblastic T-cell lymphoma: time for a second look?

A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL)

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)

Emerging drugs for T-cell lymphoma

Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era

Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study

A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma

Trends in the surgical management of stage 1 renal cell carcinoma: findings from a population‐based study

MM-040: Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m2 and Once-Weekly at 70 mg/m2 in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies

Prognostic Value of Lymph Node Ratio in Patients with Uterine Carcinosarcoma

Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasms

The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit

Use of romidepsin for the treatment of mycosis fungoides and Sezary syndrome - role of romidepsin in the current therapeutic landscape and implications for future practice

Suchergebnisse filtern